In the present study of 33 patients (38 cases) with liver cancer, 15 cases (39.47%) experienced possible drug-related adverse reactions, including 11 cases with a reduction in the number of WBCs (28.95%), seven with a reduction in the number of PLTs (18.42%), seven with increased ALT levels (18.42%), six with increased AST levels (15.79%), five with increased SDB levels (13.16%), four with a reduction in Hgb (10.53%) levels, four with neutropenia (10.53%), three with increased STB levels (7.89%), one with an increased CR (2.63%) and one with increased BUN levels (2.63%). Here, GPT is linked to liver cancer.